glp-1 drugs and parkinson's disease Repurposing Receptor Agonists for Disease: Current Evidence Future Opportunities | Pharmaceutical Medicine Neuroprotective Actions of Glucagon-Like Peptide-1

GLP-1 medications have a very low risk of hypoglycemia when used alone

Given the lack of individual preclinical models of PCOS that recapitulate all the metabolic, endocrine, and gonadal traits of the clinical syndrome, pharmacological testing was conducted in parallel in these two PCOS models, which are among the most reliable to mimic the metabolic and gonadal phenotype of women with PCOS 36,37 , capturing also the heterogeneity of this condition 38

[Google Scholar] 280.Han S.H., Ockerman K., Furnas H., Mars P., Klenke A., Ching J., Momeni A., Sorice-Virk S

Accordingly, they result in appetite control, energy expenditure, and metabolism regulation

& Kiens, B

Anecdotes are all over social media, but more importantly pharmaceutical companies are taking note of these anecdotes and starting to run trials for a plethora of indications